Evidence map›Paper›PMID 38102193›Full record

ArticleScientific reports2023

Enhanced anti-tumor activity of transferrin/folate dual-targeting magnetic nanoparticles using chemo-thermo therapy on retinoblastoma cancer cells Y79.

Elaheh Sadri, Sepideh Khoee, Samaneh Moayeri, Bahareh Haji Ali, Vahid Pirhajati Mahabadi, Sakine Shirvalilou, Samideh Khoei

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Enhancing Anticancer Effects: Targeted Doxorubicin Delivery Using UiO-66-NHJournal of materials science. Materials in medicine · 2025
    Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Elaheh SadriFinetech in Medicine Research Center, Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, P.O. Box: 1449614525, Tehran, Iran.
Sepideh KhoeeDepartment of Polymer Chemistry, School of Chemistry, College of Science, University of Tehran, Tehran, Iran.
Samaneh MoayeriDepartment of Polymer Chemistry, School of Chemistry, College of Science, University of Tehran, Tehran, Iran.
Bahareh Haji AliDepartment of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Vahid Pirhajati MahabadiCellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.
Sakine ShirvalilouFinetech in Medicine Research Center, Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, P.O. Box: 1449614525, Tehran, Iran. sakine.shirvaliloo@gmail.com.
Samideh KhoeiFinetech in Medicine Research Center, Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, P.O. Box: 1449614525, Tehran, Iran. khoei.s@iums.ac.ir.
Iran University of Medical Sciences · IRUniversity of Tehran · IR

Funding

Iran University of Medical Sciences 19384
6 · The paper itself

Abstract

Malignant neoplasms are one of the main causes of death, especially in children, on a global scale, despite strenuous efforts made at advancing both diagnostic and therapeutic modalities. In this regard, a new nanocarrier Vincristine (VCR)-loaded Pluronic f127 polymer-coated magnetic nanoparticles conjugated with folic acid and transferrin (PMNP-VCR-FA-TF) were synthesized and characterized by various methods. The cytotoxicity of these nanoparticles was evaluated in vitro and ex vivo conditions. The in vitro anti-tumor effect of the nanoparticles was evaluated by colony formation assay (CFA) and reactive oxygen species (ROS) in Y79 cell line. The results showed that nanoparticles with two ligands conferred greater toxicity toward Y79 cancer cells than ARPE19 normal cells. Under an alternating magnetic field (AMF), these nanoparticles demonstrated a high specific absorption rate. The CFA and ROS results indicated that the AMF in combination with PMNP-VCR-FA-TF conferred the highest cytotoxicity toward Y79 cells compared with other groups (P < 0.05). PMNP-VCR-FA-TF could play an important role in converting externally applied radiofrequency energy into heat in cancer cells. The present study confirmed that dual targeting chemo-hyperthermia using PMNP-VCR-FA-TF was significantly more effective than hyperthermia or chemotherapy alone, providing a promising platform for precision drug delivery as an essential component in the chemotherapy of retinoblastoma.

Indexed as

Hyperthermia, InducedMagnetite NanoparticlesNanoparticlesRetinal NeoplasmsRetinoblastomaCell Line, TumorChildFolic AcidHumansReactive Oxygen SpeciesTransferrinVincristineFolic AcidMagnetite NanoparticlesReactive Oxygen SpeciesTransferrinVincristine

Identifiers

PMID38102193
PMCPMC10724238
OpenAlexW4389778002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.